You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
研報掘金丨太平洋證券:維持恩華藥業“買入”評級,積極佈局CNS熱門領域
格隆匯 03-14 17:23

太平洋證券研報指出,恩華藥業(002262.SZ)核心產品集採風險降低,積極佈局CNS熱門領域。核心麻醉產品管制升類和改構進一步拓寬護城河公司主要鎮靜產品咪達唑侖的原料藥及注射液2024年7月1日起升類爲管制壁壘更高的紅處方管理,其國家集採風險進一步降低。本次四川牽頭的六省聯盟集採採購目錄僅納入20mg 規格的依託咪酯中/長鏈脂肪乳注射劑,未納入依託咪酯長鏈脂肪乳注射劑,公司核心麻醉產品依託咪酯地方聯盟集採風險進一步降低。此外,依託咪酯改構新藥NH600001 預計近期報產。此外,近期公司通過入股獲得三晟醫藥及其子公司的部分在研藥品(包括CNS 熱門靶點KCNQ2/3 激動劑N3T040245)未來在中國大陸的研發、生產和商業化的分許可權的優先談判權。維持“買入”評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account